Allogene Therapeutics Adds Renowned CAR T Expert, Jae Park, M.D. to its Scientific Advisory BoardGlobeNewsWire • 09/20/21
Allogene Therapeutics (ALLO) Up 9.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/03/21
Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor ConferencesGlobeNewsWire • 09/01/21
Allogene Therapeutics Receives FDA Orphan Drug Designation (ODD) for ALLO-715 for the Treatment of Multiple Myeloma (MM)GlobeNewsWire • 08/12/21
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of DirectorsGlobeNewsWire • 08/02/21
Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021GlobeNewsWire • 07/27/21
Allogene Therapeutics Granted FDA Fast Track Designation for ALLO-605, the First TurboCAR™ T Cell Therapy, for the Treatment of Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 06/30/21
Why Is Allogene Therapeutics (ALLO) Down 17.5% Since Last Earnings Report?Zacks Investment Research • 06/04/21
Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021GlobeNewsWire • 05/19/21
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Allogene Therapeutics (ALLO) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/21
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical OncologyGlobeNewsWire • 04/28/21
Allogene Therapeutics to Report First Quarter Financial Results on May 5, 2021GlobeNewsWire • 04/27/21